Oncotelic Therapeutics, Inc. (OTLC)
- Previous Close
0.0375 - Open
0.0375 - Bid --
- Ask --
- Day's Range
0.0370 - 0.0380 - 52 Week Range
0.0100 - 0.0500 - Volume
106,436 - Avg. Volume
63,224 - Market Cap (intraday)
15.188M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Aug 16, 2024 - Aug 20, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies. The company is headquartered in Agoura Hills, California.
www.oncotelic.comRecent News: OTLC
Performance Overview: OTLC
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OTLC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OTLC
Valuation Measures
Market Cap
15.19M
Enterprise Value
27.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
215.06
Price/Book (mrq)
1.25
Enterprise Value/Revenue
394.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-0.89%
Return on Equity (ttm)
-54.38%
Revenue (ttm)
70k
Net Income Avi to Common (ttm)
-7.79M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
188.99k
Total Debt/Equity (mrq)
114.62%
Levered Free Cash Flow (ttm)
-577.46k
Research Analysis: OTLC
Company Insights: OTLC
OTLC does not have Company Insights